Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (A57891) - R10 - Effective September 19, 2024

Date Posted: January 22, 2026

This Billing and Coding Article has been revised under contract numbers: 01111 (CA), 01211 (AS, GU, HI, NMI), 01311 (NV), and 01911 (CA, HI & Territories).

Effective Date: September 19, 2024

Summary of Changes:

Under Article Text added "To submit a claim for ABL1 Kinase Domain Mutation Analysis by NGS for the detection of acquired imatinib tyrosine kinase inhibitor resistance, use CPT® 81170 and one (1) UOS with the assigned DEX Z-Code. See also Group 2 below". Under CPT/HCPCS Codes Group 2: Paragraph added "The following should be reported for ABL1 Kinase Domain Mutation Analysis for the detection of acquired imatinib tyrosine kinase inhibitor resistance". Under CPT/HCPCS Codes Group 2: Codes added 81170. Under ICD-10 Codes that Support Medical Necessity Group 2: Codes added C92.10 and C92.12. This revision is effective 9/19/2024.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.

Last Updated Jan 22 , 2026